PGH Offers New Minimally Invasive Procedure for Cardiac PatientsFeb 12, 2020
Hialeah, Florida (June 22, 2015) - The Heart Institute at Palmetto General Hospital now gives patients suffering from severe aortic stenosis (AS) an alternative treatment option to open heart surgery. Transcatheter aortic valve replacement (TAVR) is a minimally invasive procedure that involves the placement of a balloon-expandable heart valve into the body using a catheter.
“At Palmetto General Hospital, we are constantly researching the latest technologies and procedures to meet the ever-changing needs of our patients,” said CEO Ana Mederos. “We are excited to enhance our medical services with the addition of TAVR and offer aortic stenosis patients a new option.”
TAVR is available for patients who do not qualify for open heart procedures. The Edwards SAPIEN Transcatheter Heart Valve, which is approved by the U.S. Food and Drug Administration (FDA), is designed to replace a patient’s diseased native aortic valve while the heart continues to beat. This avoids the need to stop the patient’s heart and connect him or her to a heart-lung machine during surgery.
Up to 1.5 million people in the United States suffer from AS, a progressive disease that affects the aortic valves. Some people develop severe symptomatic AS, resulting in debilitating symptoms. While about two-thirds of these patients undergo surgery, many are deemed inoperable and have no effective treatment options available. Studies indicate that 50 percent of these patients will not survive more than an average of two years after the onset of symptoms.
For more information on the resources available at The Heart Institute at Palmetto General Hospital, please visit www.palmettogeneral.com or call 305-823-5000.